ERYTECH Pharma Stock Forecast, Price & News

ERYTECH Pharma (NASDAQ:ERYP) Frequently Asked Questions

Is ERYTECH Pharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ERYTECH Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERYP, but not buy additional shares or sell existing shares.
View analyst ratings for ERYTECH Pharma or view top-rated stocks.

How has ERYTECH Pharma's stock price been impacted by Coronavirus (COVID-19)?

ERYTECH Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ERYP stock has decreased by 54.0% and is now trading at $2.41.
View which stocks have been most impacted by COVID-19.

Are investors shorting ERYTECH Pharma?

ERYTECH Pharma saw a decrease in short interest in November. As of November 15th, there was short interest totaling 8,500 shares, a decrease of 57.1% from the October 31st total of 19,800 shares. Based on an average daily volume of 93,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short.
View ERYTECH Pharma's Short Interest.

Who are ERYTECH Pharma's key executives?

ERYTECH Pharma's management team includes the following people:

• Gil Beyen, Chief Executive Officer & Director
• Eric Soyer, Chief Operating & Financial Officer
• Stewart Craig, Chief Technical Officer
• Iman El-Hariry, Chief Medical Officer
• Jérôme Bailly, Chief Quality Officer & Deputy General Manager

Who are some of ERYTECH Pharma's key competitors?

Some companies that are related to ERYTECH Pharma include Surface Oncology (SURF), Fusion Pharmaceuticals (FUSN), Environmental Impact Acquisition (ENVI), Outlook Therapeutics (OTLK), INmune Bio (INMB), Black Diamond Therapeutics (BDTX), aTyr Pharma (LIFE), Eiger BioPharmaceuticals (EIGR), Cardiff Oncology (CRDF), Tscan Therapeutics (TCRX), Harpoon Therapeutics (HARP), Solid Biosciences (SLDB), Achilles Therapeutics (ACHL), TCR2 Therapeutics (TCRR) and Aptose Biosciences (APTO).
View all of ERYP's competitors.

What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD).

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

Who are ERYTECH Pharma's major shareholders?

ERYTECH Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%).

Which major investors are buying ERYTECH Pharma stock?

ERYP stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $2.41.

How much money does ERYTECH Pharma make?

ERYTECH Pharma has a market capitalization of $67.30 million and generates $4.25 million in revenue each year.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 2,020 workers across the globe.

What is ERYTECH Pharma's official website?

The official website for ERYTECH Pharma is www.erytech.com.

Where are ERYTECH Pharma's headquarters?

ERYTECH Pharma is headquartered at 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438, via email at [email protected], or via fax at 33-4-78-75-56-29.